![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Materials)
1MB |
| Item Type: | Article |
|---|---|
| Title: | Enhanced biosafety of the Sleeping Beauty transposon system by using mRNA as source of transposase to efficiently and stably transfect retinal pigment epithelial cells |
| Creators Name: | Harmening, N. and Johnen, S. and Izsvák, Z. and Ivics, Z. and Kropp, M. and Bascuas, T. and Walter, P. and Kreis, A. and Pajic, B. and Thumann, G. |
| Abstract: | Neovascular age-related macular degeneration (nvAMD) is characterized by choroidal neovascularization (CNV), which leads to retinal pigment epithelial (RPE) cell and photoreceptor degeneration and blindness if untreated. Since blood vessel growth is mediated by endothelial cell growth factors, including vascular endothelial growth factor (VEGF), treatment consists of repeated, often monthly, intravitreal injections of anti-angiogenic biopharmaceuticals. Frequent injections are costly and present logistic difficulties; therefore, our laboratories are developing a cell-based gene therapy based on autologous RPE cells transfected ex vivo with the pigment epithelium derived factor (PEDF), which is the most potent natural antagonist of VEGF. Gene delivery and long-term expression of the transgene are enabled by the use of the non-viral Sleeping Beauty (SB100X) transposon system that is introduced into the cells by electroporation. The transposase may have a cytotoxic effect and a low risk of remobilization of the transposon if supplied in the form of DNA. Here, we investigated the use of the SB100X transposase delivered as mRNA and showed that ARPE-19 cells as well as primary human RPE cells were successfully transfected with the Venus or the PEDF gene, followed by stable transgene expression. In human RPE cells, secretion of recombinant PEDF could be detected in cell culture up to one year. Non-viral ex vivo transfection using SB100X-mRNA in combination with electroporation increases the biosafety of our gene therapeutic approach to treat nvAMD while ensuring high transfection efficiency and long-term transgene expression in RPE cells. |
| Keywords: | nvAMD, PEDF, RPE Cells, Gene Therapy, Non-Viral, Sleeping Beauty Transposase, mRNA |
| Source: | Biomolecules |
| ISSN: | 2218-273X |
| Publisher: | MDPI |
| Volume: | 13 |
| Number: | 4 |
| Page Range: | 658 |
| Date: | 7 April 2023 |
| Official Publication: | https://doi.org/10.3390/biom13040658 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
